Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference

Rhea-AI Summary

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that CEO Bobak Azamian will participate in a fireside chat at the Raymond James 2021 Human Health Innovation Conference on June 22 at 12 PM ET. The chat will provide a corporate update on Tarsus's focus on unmet medical needs in eye care and other therapeutic areas. Tarsus is currently conducting clinical trials for its lead product TP-03, targeting Demodex blepharitis and Meibomian Gland Disease, and TP-05, aimed at preventing Lyme disease. The webcast will be available for replay on their official site for 90 days.

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus, will provide a brief corporate update during a fireside chat at the Raymond James 2021 Human Health Innovation Conference.

Fireside Chat Details
Date: Tuesday, June 22
Time: 12:00 PM ET/ 9:00 AM PT
Webcast: https://kvgo.com/rj-health/tarsus-pharmaceuticals-inc-june-2021

The live webcast will be hosted on ir.tarsusrx.com and available for replay for a period of 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.

Media Contact:
SuJin Oh
Shop PR
(917) 841-5213
sujin@shop-pr.com
Investor Contact:
Patti Bank
Westwicke Partners, an ICR company
(415) 513-1284
IR@tarsusrx.com

FAQ

What will Tarsus Pharmaceuticals discuss at the Raymond James conference on June 22, 2021?

Tarsus Pharmaceuticals will provide a corporate update regarding their projects, including their investigational medicines for eye care.

What time is Tarsus Pharmaceuticals' presentation at the Raymond James Human Health Innovation Conference?

The presentation is scheduled for June 22, 2021, at 12 PM ET.

Where can I watch the Tarsus Pharmaceuticals webcast from the Raymond James conference?

The webcast will be available on Tarsus Pharmaceuticals' official site and can be replayed for 90 days.

What is Tarsus Pharmaceuticals' lead product candidate?

Tarsus's lead product candidate is TP-03, which is in a Phase 3 trial for treating Demodex blepharitis.

What other products is Tarsus Pharmaceuticals developing?

Tarsus is also developing TP-05, an oral therapeutic for Lyme disease prevention, currently in Phase 1 trials.